이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bausch + Lomb 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Brent Saunders

최고 경영자

US$45.3m

총 보상

CEO 급여 비율	3.1%
CEO 임기	1.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.2yrs
이사회 평균 재임 기간	2.1yrs

최근 관리 업데이트

Recent updates

Little Excitement Around Bausch + Lomb Corporation's (NYSE:BLCO) Revenues

Jun 22

Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner

May 24

Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate

Apr 30

Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price

Jan 14

Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)

Nov 08

Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S

Nov 03

An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued

Aug 15

Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease

Aug 09

These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong

May 09

Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate

Mar 28

Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M

Feb 22

Bausch + Lomb's photodynamic laser gets FDA approval for use with Visudyne

Feb 01

Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect

Jan 24

Bausch + Lomb acquires AcuFocus for cataract lens

Jan 17

Bausch + Lomb says Joseph Papa to serve as CEO until at least March next year

Dec 22

Bausch + Lomb stock rises on FDA nod for contact lens rehydrating drops

Dec 13

Bausch + Lomb: A Solid Play In Challenging Economic Times

Nov 09

CEO 보상 분석

Brent Saunders 의 보수는 Bausch + Lomb 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$337m
Dec 31 2023	US$45m	US$1m	-US$260m

보상 대 시장: Brent 의 총 보상 ($USD 45.31M )은 US 시장( $USD 8.45M ).

보상과 수익: Brent 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Brent Saunders (54 yo)

1.3yrs

테뉴어

US$45,309,051

보상

Mr. Brenton L. Saunders, J. D., also known as Brent, is CEO & Chairman of the Board at Bausch & Lomb Incorporated since 2023. He is CEO & Chairman of the Board at Bausch + Lomb Corporation since March 06,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Brenton L. Saunders	CEO & Chairman	1.3yrs	US$45.31m	데이터 없음
Osama Eldessouky	Executive VP & CFO	2.4yrs	US$4.76m	0.0048% $ 249.9k
A. Robert Bailey	Executive VP & Chief Legal Officer	1.2yrs	US$5.21m	0.0086% $ 451.6k
Yehia Hashad	Executive VP of Research & Development and Chief Medical officer	2.4yrs	US$2.66m	0.0032% $ 170.3k
Andrew Stewart	President of Global Pharmaceuticals & International Consumer	1.4yrs	US$1.93m	0.0020% $ 105.8k
Alan Waterhouse	Executive VP and Chief Supply Chain & Operations Officer	1.4yrs	데이터 없음	데이터 없음
Frederick Munsch	Senior VP	no data	데이터 없음	0.0011% $ 60.2k
Jonathon Kellerman	Chief Compliance Officer	less than a year	데이터 없음	데이터 없음
T.J. Crawford	Chief Communications Officer	less than a year	데이터 없음	데이터 없음
Manisha Narasimhan	Chief Corporate Development & Digital Officer	less than a year	데이터 없음	데이터 없음
Asli Gevgilili	Executive VP & Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음
Luc Bonnefoy	President of Surgical	no data	데이터 없음	0.0040% $ 210.6k

1.2yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: BLCO 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Brenton L. Saunders	CEO & Chairman	1.3yrs	US$45.31m	데이터 없음
Thomas Ross	Lead Independent Director	1.3yrs	US$396.30k	0.0036% $ 186.0k
John Paulson	Independent Director	2.2yrs	US$312.46k	0.0072% $ 377.7k
Sarah Kavanagh	Independent Director	2.2yrs	US$337.50k	0.0016% $ 86.4k
Brett Icahn	Independent Director	2yrs	US$312.50k	0.0074% $ 388.7k
Russel Robertson	Independent Director	2.2yrs	US$327.45k	0.0037% $ 194.4k
Andrew von Eschenbach	Independent Director	2.2yrs	US$327.50k	0.0036% $ 186.0k
Karen Ling	Independent Director	less than a year	데이터 없음	0.00075% $ 39.3k
Nathalie Bernier	Independent Director	2.2yrs	US$324.95k	0.000060% $ 3.1k
Gaoxiang Hu	Independent Director	2yrs	US$335.00k	0.0074% $ 388.7k

2.1yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: BLCO 의 이사회는 경험(평균 재직 기간 2.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Bausch + Lomb 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Bausch + Lomb Corporation, Annual General Meeting, May 29, 2024

High number of new directors

Bausch + Lomb Corporation Announces Board Changes

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation Announces Board Appointments, Effective March 6, 2023

Recent updates

Little Excitement Around Bausch + Lomb Corporation's (NYSE:BLCO) Revenues

Bausch + Lomb Corporation Announces the U.S. Introduction of Bausch + Lomb Infuse for Astigmatism Daily Disposable Contact Lenses

Bausch + Lomb Corporation Launches Blink™ NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States

Bausch + Lomb Corporation Receives Health Canada Approval for Envista Envy™? Full Visual Range Intraocular Lens

Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner

Consensus EPS estimates fall by 111%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate

Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

Bausch + Lomb Corporation to Report Q1, 2024 Results on May 01, 2024

Bausch + Lomb Corporation, Annual General Meeting, May 29, 2024

Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?

High number of new directors

Bausch + Lomb Corporation Announces Board Changes

Consensus EPS estimates fall by 147%, revenue upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2024

Many Still Looking Away From Bausch + Lomb Corporation (NYSE:BLCO)

Bausch + Lomb Corporation to Report Q4, 2023 Results on Feb 21, 2024

Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound

Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price

Bausch + Lomb Corporation Receives FDA Approval for TENEO Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)

New major risk - Financial position

Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Raises Revenue Guidance for the Full Year of 2023

Bausch + Lomb Will Present New Scientific Data and Analyses At American Academy of Ophthalmology Annual Meeting

Consensus EPS estimates upgraded to US$0.58 loss

Bausch + Lomb Corporation to Report Q3, 2023 Results on Nov 01, 2023

Consensus EPS estimates fall by 235%, revenue upgraded

Bausch + Lomb Corporation Launches LUMIFY EYE ILLUMINATIONS in the United States

Bausch + Lomb Corporation Launches MIEBO (Perfluorohexyloctane Ophthalmic Solution) in the United States

An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued

Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Announces Executive Changes

Now 21% undervalued

Bausch + Lomb Corporation to Report Q2, 2023 Results on Aug 02, 2023

Bausch + Lomb Corporation (NYSE:BLCO) agreed to acquire Blink® product line of eye and contact lens drops of Johnson & Johnson Vision for approximately $110 million.

Bausch + Lomb Corporation (NYSE:BLCO) signed an agreement to acquire ophthalmology assets from Novartis AG (SWX:NOVN) for $2.5 billion.

Bausch + Lomb Launches PreserVision AREDS 2 Formula Soft Gels Plus CoQ10 in the United States

Bausch + Lomb Corporation to Present the Results of 11 Scientific Poster Presentations Inviding the Company's Consumer, Vision Care and Pharmaceutical Products

Bausch + Lomb Corporation Launches Biotrue Hydration Boost Contact Lens Rehydrating Drops in the United States

Bausch + Lomb Corporation Launches Bausch + Lomb Infuse®? Multifocal Silicone Hydrogel Contact Lenses in the United States

Bausch + Lomb Corporation Announces Executive Changes

Bausch + Lomb Corporation and Novaliq Announce Fda Approval of Miebo™? (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch + Lomb Corporation Provides Earnings Guidance for the Year 2023

Consensus EPS estimates fall by 30%

Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 45%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M

Now 21% undervalued

Bausch + Lomb Corporation Announces Board Appointments, Effective March 6, 2023

Bausch + Lomb and Modulight Announces FDA Approval of ML6710i Photodynamic Laser

Bausch + Lomb's photodynamic laser gets FDA approval for use with Visudyne

Bausch + Lomb Corporation, Annual General Meeting, Apr 24, 2023

Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect

Bausch + Lomb Corporation to Report Q4, 2022 Results on Feb 22, 2023

Bausch + Lomb Corporation (NYSE:BLCO) acquired AcuFocus, Inc.

Bausch + Lomb acquires AcuFocus for cataract lens

Bausch + Lomb Corporation Announces the U.S. Introduction of Preservision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

Bausch + Lomb Corporation Enters into CEO Separation Agreement with Joseph C. Papa